Morgan Stanley Lifts Pfizer (PFE) Price Target, Keeps Equalweight Rating

Pfizer Inc. (NYSE:PFE) is one of the 10 Best Affordable Stocks Under $50 to Buy. On August 5, Morgan Stanley increased its price target for Pfizer Inc. (NYSE:PFE) from $32 to $33 while keeping an Equalweight rating.

This decision came after Pfizer Inc. (NYSE:PFE) released its Q2 2025 earnings report. The company continues to navigate policy changes in the pharmaceutical sector.

The firm highlighted that Pfizer Inc.’s (NYSE:PFE) guidance accounts for the impact of tariffs from China, Canada, and Mexico. It also reflects potential price changes based on a recent letter received from President Trump.

In its outlook, Pfizer Inc. (NYSE:PFE) reaffirmed its full-year 2025 revenue guidance. The company increased its adjusted diluted EPS forecast by $0.10 at the midpoint to a range of $2.90 to $3.10.

This higher adjusted diluted EPS guidance is supported by Pfizer Inc.’s (NYSE:PFE) strong performance, continued confidence in the company’s business, a favorable impact from foreign exchange, cost improvement initiatives, and an improved effective tax rate.

Pfizer Inc. (NYSE:PFE) is a leading pharmaceutical company that focuses on the discovery, development, and manufacture of healthcare products, medicines, and vaccines.

While we acknowledge the potential of PFE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 11 Best Revenue Growth Stocks to Buy Now and 11 Best Under-the-Radar Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.